BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ebbers HC, Pieper B, Issa A, Addison J, Freudensprung U, Rezk MF. Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. Rheumatol Ther 2019;6:317-38. [PMID: 31385263 DOI: 10.1007/s40744-019-00169-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Horta-baas G. Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake? PROM 2022;Volume 13:79-95. [DOI: 10.2147/prom.s256715] [Reference Citation Analysis]
2 Gill J, Barry R, Sreekantam S, Mohammed B. Multi-modal Imaging in Etanercept-induced Uveitis: A Case Series. TOOPHTJ 2020;14:70-4. [DOI: 10.2174/1874364102014010070] [Reference Citation Analysis]
3 Kurki P, Kang HN, Ekman N, Knezevic I, Weise M, Wolff-Holz E. Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs 2022. [PMID: 35596890 DOI: 10.1007/s40259-022-00533-x] [Reference Citation Analysis]
4 Bruni C, Gentileschi S, Pacini G, Baldi C, Capassoni M, Tofani L, Bardelli M, Cometi L, Cantarini L, Nacci F, Vietri M, Bartoli F, Fiori G, Frediani B, Matucci-Cerinic M. The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. Ther Adv Musculoskelet Dis 2020;12:1759720X20964031. [PMID: 33133246 DOI: 10.1177/1759720X20964031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Gasteiger C, den Broeder AA, Stewart S, Gasteiger N, Scholz U, Dalbeth N, Petrie KJ. The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychol Rev 2021;:1-21. [PMID: 34409923 DOI: 10.1080/17437199.2021.1970610] [Reference Citation Analysis]
6 Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 2021;:1-16. [PMID: 33567923 DOI: 10.1080/14712598.2021.1889511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fisher A, Kim JD, Carney G, Dormuth C. Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia. BMC Rheumatol 2022;6. [DOI: 10.1186/s41927-021-00235-x] [Reference Citation Analysis]
8 Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R. An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther 2022. [PMID: 35278204 DOI: 10.1007/s40123-022-00488-w] [Reference Citation Analysis]
9 Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 2021;81:1859-79. [PMID: 34705255 DOI: 10.1007/s40265-021-01610-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]